Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 26.
doi: 10.1007/s00210-025-04394-3. Online ahead of print.

Morin: a promising hepatoprotective agent against drug and chemical-induced liver injury

Affiliations
Review

Morin: a promising hepatoprotective agent against drug and chemical-induced liver injury

Anandakumar Pandi et al. Naunyn Schmiedebergs Arch Pharmacol. .

Abstract

Morin, a naturally occurring flavonoid found in various fruits and medicinal plants, has long been recognized in ethnopharmacological practices for its therapeutic potential. While its antioxidant and anti-inflammatory properties have been appreciated historically, recent molecular studies have begun to uncover the precise mechanisms underlying its protective actions, particularly in the context of liver toxicity induced by drugs and chemicals. Morin has demonstrated significant hepatoprotective effects through its ability to attenuate oxidative stress, suppress pro-inflammatory cytokines, and regulate apoptotic pathways in hepatocytes. Multiple cellular targets and signaling pathways, including Nrf2/HO-1, NF-κB, MAPK, SphK1/S1P, and ADMA/DDAH, have been shown to be modulated by morin, indicating its multi-faceted protective profile. This review explores the molecular mechanisms of morin to enhance understanding of its therapeutic potential and support its future clinical application against drug- and chemical-induced liver injury.

Keywords: Anti-apoptotic; Anti-inflammatory; Antioxidant; Liver; Morin; Pre-clinical.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.

Similar articles

Cited by

References

    1. Addissouky TA (2024) Translating molecular heterogeneity into precision medicine for advanced liver disease. Arch Gastroenterol Res 5(1):47–58 - DOI
    1. Ahmed M (2022) Functional, diagnostic and therapeutic aspects of bile. Clin Exp Gastroenterol 15:105–120 - PubMed - PMC - DOI
    1. Ajoolabady A, Kaplowitz N, Lebeaupin C, Kroemer G, Kaufman RJ, Malhi H, Ren J (2023) Endoplasmic reticulum stress in liver diseases. Hepatology 77(2):619–639 - PubMed - DOI
    1. Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A (2023) Drug induced liver injury - a 2023 update. J Toxicol Environ Health B Crit Rev 26(8):442–467 - PubMed - DOI
    1. Altyar AE, Kensara OA, Sayed AA et al (2023) Acute aflatoxin B1-induced hepatic and cardiac oxidative damage in rats: ameliorative effects of morin. Heliyon 9(11):e21837 - PubMed - PMC - DOI

LinkOut - more resources